Fispari
I agree that the rapid approach of the reporting of the phase 3 results for Narso in IGA us a hopeful note. At this point, there is competition for that market. A competitor was granted accelerated approval about a month ago. Copy and paste the following link to arrive at the company web site for it. Choosing the "Health Care Provider" option is recommended.:
https://filsparihcp.com/igan/?gclid=Cj0KCQjwt_qgBhDFARIsABcDjOcSHWxS5pPxNevlw1NA41mB4_uQMXK4DKfzlM_U3-VF4pBNdPi5sqUaAhGdEALw_wcB#MOA
The AA was based upon proteinurea reduction of 45%. Back in the phase 2 for Narso, it was reported that Narso showed a 54% reduction. It would seem that if the phase 3 results were similiar, that might be a statistic upon which Narso could be claimed to have a competitive advantage. On the other hand, that magnitude of difference might not show up with the larger phase 3 difference, and Narso could still be much lower.
$9,900 a month is being charged for Filspari, at "wholesale prices." It was granted approval based on proteinuria for a full approval, and those are unlikely to be an issue for Narso. So, while Filspari appears to won the race for first to get approval and get to market, the race may not be entirely over. (And there are also still others still in IGAN race.)